Ignite Creation Date:
2025-12-24 @ 2:59 PM
Ignite Modification Date:
2025-12-30 @ 9:36 AM
Study NCT ID:
NCT01383759
Status:
COMPLETED
Last Update Posted:
2020-04-07
First Post:
2011-06-27
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-06-24
Start Date Type:
ACTUAL
Primary Completion Date:
2019-04-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-04-30
Completion Date Type:
ACTUAL
First Submit Date:
2011-06-27
First Submit QC Date:
None
Study First Post Date:
2011-06-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-03-16
Results First Submit QC Date:
None
Results First Post Date:
2020-03-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-03-30
Last Update Post Date:
2020-04-07
Last Update Post Date Type:
ACTUAL